香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 截至本公告日期，本公司仍在落實本集團2024財年的綜合年度業績。本公告所 載資料乃基於對本集團未經審核綜合管理賬目的初步審閱以及董事會目前可 獲得的2024財年的資料，其尚未經本公司核數師審閱或審核，亦未經董事會審 核委員會審閱。謹請股東及潛在投資者細閱本公司2024財年的年度業績公告， 而有關公告預期將於2025年3月底刊發。 – 2 – 有關截至2024年12月31日止財政年度之財務資料的利潤狀況更新 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定義見香 港聯合交易所有限公司證券上市規則（「上市規則」））及上市規則第13.09(2)(a)條 作出 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 根據股份獎勵計劃購買股份 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出。 茲提述本公司日期為2024年8月28日的公告（「該公告」），內容有關本公司董事 （「董事」）會（「董事會」）採納股份獎勵計劃（「本計劃」），以及本公司日期為2024 年11月18日的公告，內容有關受託人根據本計劃購買股份。除文義另有所指外， 本公告所用詞彙與該公告所界定者具有相同涵義。 本公司獲受託人告知，自2024年11月19日起至2025年1月23日止，受託人已動用 約12.78百萬港元於市場上按每股約9.67港元的平均代價購買合共1,322,400股股 份（佔於本公告日期已發行股份總數約0.89%）。截至本公告日期，受 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 角膜共聚焦顯微鏡獲准入創新產品註冊程序 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於近日，本公司全資附屬公司高 視創新科技有限公司（「高視創新」）自主研發的角膜共聚焦顯微鏡經江蘇省藥 品監督管理局審查並同意進入創新產品註冊程序。 截至本公告日期，董事會包括主席兼執行董事高鐵塔先生，執行董事劉新偉先生、趙新禮先 生、張建軍先生及李文奇女士，非執行董事David Guowei Wang博士，以及獨立非執行董事馮 昕先生、王立新先生及陳帆城先生。 – 2 – 在眼科顯微成像領域，寬視場與高分辨的制 ...

茲提述本公司日期為2024年8月28日的公告（「該公告」），內容有關本公司董事 （「董事」）會（「董事會」）採納股份獎勵計劃（「本計劃」）。除文義另有所指外，本 公告所用詞彙與該公告所界定者具有相同涵義。 自願公告 根據股份獎勵計劃購買股份 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 本公司獲受託人告知，自2024年10月4日起至2024年11月18日止，受託人已動用 約5.14百萬港元於市場上按每股約10.77港元的平均代價購買合共477,200股股份 （佔於本公告日期已發行股份總數約0.32%）。據此購買的股份將用作本計劃項 下合資格參與者的獎勵，以激勵彼等為本集團作出貢獻。此外，本次購買股份 亦顯 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 高视医疗科技有限公司 (於開曼群島註冊成立的有限責任公司) 呈交日期： 2024年11月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02407 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 人工晶狀體植入系統獲得醫療器械註冊證 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本集團全資附屬公司高視泰靚 醫療科技有限公司（「高視泰靚」）之「人工晶狀體植入系統」已獲得由廣東省藥 品監督管理局批准的二類醫療器械註冊證。 高 視 泰 靚 本 次 獲 批 的 人 工 晶 狀 體 植 入 系 統（註 冊 證 編 號 ： 粵 械 注 准 20242161490）由高視泰靚自主設計完成，既可以用於白內障手術中的人工晶狀 體植入手術，也可用於矯正近視的有晶體眼人工晶狀體植入手術。該產品一方 面可滿足本 ...

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of RMB 642.0 million, a decrease of 8.4% compared to RMB 700.7 million for the same period in 2023[23]. - The net profit for the same period was RMB 26.9 million, down 75.6% from RMB 110.4 million in the prior year[23]. - Basic earnings per share for the six months ended June 30, 2024, were RMB 0.19, compared to RMB 0.75 for the same period in 2023[23]. - Total revenue for the six months ended June 30, 2024, was RMB 529.1 million, a decrease of 10.8% from RMB 593.2 million for the same period in 2023[39]. - Gross profit decreased by 16.1% to RMB 298.4 million for the six months ended June 30, 2024, compared to RMB 355.6 million for the same period in 2023, with a gross margin decline from 50.8% to 46.5%[40]. - The technical services segment generated revenue of RMB 110.0 million, representing a year-on-year increase of 6.5%[29]. - Profit before tax decreased to RMB 58,395,000, a decline of 58.9% from RMB 142,229,000 in the previous year[100]. - Total comprehensive income for the period was RMB 7,110,000, down from RMB 147,170,000 in the same period last year[103]. Research and Development - Research and development expenses increased by 34.5% to RMB 35.1 million, representing 5.5% of revenue, up from 3.7% in the previous year[23]. - The company has expanded its R&D capabilities with platforms in four cities in China and two in Europe, covering a global sales network across 51 countries[25]. - The company has established a "global 4+2" R&D layout with a total of 261 R&D personnel, representing approximately 29.9% of total employees[30]. - Research and development expenses rose by 34.5% to RMB 35.1 million, reflecting ongoing investments in product development and team expansion[47]. - Research and development expenses increased to RMB 35,140,000, up 34.6% from RMB 26,105,000 in the previous year[123]. Product and Market Development - The company has a product portfolio of 150 items, including 65 proprietary products, and has established exclusive distribution agreements with 16 overseas brand partners[25][28]. - Revenue contribution from proprietary products was RMB 178.0 million, accounting for 33.6% of total sales, an increase from 32.7% in the previous year[27]. - The company is focusing on the development of surgical treatment products, particularly surgical equipment and consumables[35]. - The company has expanded its distribution network, partnering with 18 overseas brands, including exclusive agreements with 16 partners[33]. - The company aims to enhance its operational efficiency and strengthen brand and talent development as part of its long-term strategy[35]. Financial Position and Cash Flow - Cash and cash equivalents decreased by 11.6% from RMB 618.7 million as of December 31, 2023, to RMB 546.8 million as of June 30, 2024, mainly due to repayment of domestic loans[61]. - The debt-to-asset ratio increased from 39.1% as of December 31, 2023, to 40.2% as of June 30, 2024[65]. - Total liabilities decreased to RMB 1,251,830,000 from RMB 1,146,731,000 at the end of 2023, indicating a shift in financial structure[105]. - Operating cash flow for the six months ended June 30, 2024, was RMB (10,829) thousand, a significant decrease from RMB 111,187 thousand in the same period of 2023[109]. - The company reported a net cash outflow from financing activities of RMB (59,304) thousand in 2024, compared to RMB (70,433) thousand in 2023, indicating a decrease in outflow of about 16%[110]. Shareholder Information - The largest shareholder, GT HoldCo, holds 42.75% of the issued share capital, amounting to 63,263,528 shares[90]. - As of June 30, 2024, the company had a total of 147,970,369 issued ordinary shares[2]. - The board of directors did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[77]. - The company has adopted a share incentive plan to recognize and reward contributions from eligible participants, with no rewards granted under this plan as of the interim report date[72]. Foreign Exchange and Risk Management - The company reported a foreign exchange loss of RMB 198 million due to fluctuations in the Euro exchange rate during the reporting period[67]. - The company has no foreign currency hedging policy in place and continues to monitor foreign exchange risks[67]. - The company has implemented a credit verification process for all traders engaging in credit transactions[68]. Employee and Management Information - The total employee cost for the reporting period was RMB 184 million, an increase from RMB 169.6 million for the same period last year[71]. - The company had a total of 872 employees as of June 30, 2024, compared to 869 employees as of December 31, 2023[71]. - Total remuneration for key management personnel reached RMB 4,263,000 for the six months ended June 30, 2024, up from RMB 3,632,000 in 2023, reflecting a growth of 17.4%[162]. Acquisitions and Investments - The company completed the acquisition of Teleon Holding B.V. for €24.25 million, enhancing its product portfolio[174]. - The group’s investment in private equity funds amounted to RMB 178,696,000, with an expected return rate between 2.5% and 4.5% annually[143].

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of RMB 642.0 million, a decrease of 8.4% compared to RMB 700.7 million in the same period of 2023[2]. - The net profit for the same period was RMB 26.9 million, down 75.6% from RMB 110.4 million in 2023[2]. - Basic earnings per share were RMB 0.19, compared to RMB 0.75 in the same period of 2023[2]. - Gross profit fell from RMB 355.6 million for the six months ended June 30, 2023, to RMB 298.4 million for the same period in 2024, a decrease of 16.1%[17]. - The gross margin decreased from 50.8% to 46.5%, mainly due to increased raw material and labor costs, changes in product sales mix, and a significant price drop for artificial lenses starting May 2024[18]. - Total comprehensive income for the period was RMB 7,110 thousand, significantly lower than RMB 147,170 thousand in 2023[60]. - The company's total equity was RMB 1,555,941 thousand, down from RMB 1,696,986 thousand at the end of 2023[63]. Revenue Breakdown - Revenue contribution from proprietary products was RMB 178.0 million, accounting for 33.6% of total sales, an increase from 32.7% in the previous year[6]. - Revenue from distribution products was RMB 351.0 million, a decrease of 12.1% due to ongoing impacts from domestic medical service policies and macroeconomic conditions[7]. - Revenue from self-owned products was RMB 178,005,000, down from RMB 193,868,000, representing a decline of 8.9%[67]. - Revenue from distribution products was RMB 351,048,000, a decrease of 12.1% from RMB 399,365,000[67]. - Revenue from ophthalmic medical devices was RMB 273,009,000, down from RMB 337,863,000, a decrease of 19.3%[70]. - Revenue from technical services increased to RMB 110,047,000, up from RMB 103,325,000, marking a growth of 6.6%[70]. Research and Development - Research and development expenses increased by 34.5% to RMB 35.1 million, representing 5.5% of revenue, up from 3.7% in 2023[2]. - The company's R&D expenditure reached RMB 35.1 million, a year-on-year increase of 34.5%, accounting for 19.7% of self-owned product revenue[9]. - The company has accelerated the development of domestic artificial lenses, obtaining medical device registration certificates ahead of schedule[4]. - The company has established a global R&D layout of "4+2" with 261 R&D personnel, representing approximately 29.9% of total employees[9]. - The company is investing €5 million in R&D for the development of advanced ophthalmic devices[99]. Expenses and Costs - Sales and distribution expenses slightly decreased by 4.5% to RMB 115.5 million, while the percentage of these expenses to revenue increased from 17.3% to 18.0%[21]. - Administrative expenses increased by 17.8% to RMB 73.6 million, mainly due to staff expansion in administrative departments[22]. - Financing costs decreased by 13.1% to RMB 20.6 million, attributed to the repayment of domestic loans and lower interest rates on new loans[23]. - Other expenses rose significantly from RMB 1.9 million to RMB 12.0 million, mainly due to increased inventory impairment provisions and foreign exchange losses[25]. Inventory and Assets - Inventory increased by 11.6% to RMB 366.7 million, leading to an increase in inventory turnover days from 159 to 187 days[29]. - Non-current assets totaled RMB 1,421,150 thousand as of June 30, 2024, compared to RMB 1,452,881 thousand at the end of 2023[61]. - Current assets amounted to RMB 1,386,621 thousand, slightly down from RMB 1,390,836 thousand at the end of 2023[61]. - Trade receivables, net of impairment, amounted to RMB 143,783,000 as of June 30, 2024, compared to RMB 146,543,000 as of December 31, 2023[87]. Liabilities and Financing - The group's interest-bearing bank and other borrowings amounted to RMB 568.2 million as of June 30, 2024, including short-term borrowings of RMB 216.2 million and long-term borrowings of RMB 352.0 million[38]. - The debt-to-asset ratio increased from 39.1% as of December 31, 2023, to 40.2% as of June 30, 2024[40]. - The company plans to utilize a financing agreement of EUR 52.5 million to refinance existing loans, with a maturity date set for December 22, 2027[92]. Market and Strategic Initiatives - The company plans to enhance its product offerings in surgical treatment, focusing on surgical equipment and consumables[13]. - The company aims to strengthen its market presence in Asia and Europe while balancing domestic and international business growth[13]. - Market expansion efforts are focused on the Greater China region, with a target of increasing market share by 10%[97]. - The company has completed the acquisition of Teleon Holding B.V. for €24.25 million, enhancing its product portfolio[98]. - The company plans to enhance its distribution network in Europe, aiming for a 15% increase in sales through new partnerships[99]. Shareholder Returns and Dividends - The board does not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous period[49]. - The company announced a proposed final dividend of HKD 1.10 per share for the year ended December 31, 2023[82]. Audit and Compliance - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with financial reporting and risk management[54]. - The interim condensed consolidated financial statements for the six months ended June 30, 2024, were reviewed by the external auditor, Ernst & Young[56].

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 1,406.2 million, an increase of 12.2% compared to RMB 1,253.8 million for the year ended December 31, 2022[8]. - The net profit for the year ended December 31, 2023, was RMB 172.9 million, a significant improvement from a net loss of RMB 352.7 million in 2022, and an increase of 9.9% compared to the adjusted net profit of RMB 157.3 million for 2022[8]. - Basic earnings per share for the year ended December 31, 2023, were RMB 1.17, compared to a basic loss per share of RMB 3.61 for the year ended December 31, 2022[8]. - The gross profit for the year was RMB 691.6 million, an increase of 10.6% compared to the previous year[14]. - The company's revenue increased by 12.2% from RMB 1,253.8 million in 2022 to RMB 1,406.2 million in 2023, driven by higher sales of ophthalmic medical consumables and equipment[30]. - The gross profit increased by 10.6% from RMB 625.3 million in 2022 to RMB 691.6 million in 2023, with a slight decrease in gross margin from 49.9% to 49.2% due to rising material costs[33]. Dividend and Shareholder Information - The board proposed a final dividend of HKD 1.1 per share for the year ended December 31, 2023, compared to no dividend in 2022[8]. - The annual general meeting for shareholder approval of the proposed dividend is scheduled for May 30, 2024[8]. - The expected distribution date for the approved dividend is July 26, 2024[8]. - The company’s distributable reserves as of December 31, 2023, were approximately RMB 855.4 million, an increase from RMB 822.2 million as of December 31, 2022[100]. Research and Development - The company has been engaged in research and development of a wide range of ophthalmic medical equipment and consumables for over 20 years[3]. - The company has established a global "4+2" R&D layout, with domestic bases in four Chinese cities and two overseas in the Netherlands and Germany[14]. - The company plans to increase investment in R&D and production, focusing on expanding its product range and enhancing its presence in high-end medical devices[11]. - The company's R&D expenditure was RMB 52.9 million, accounting for 13.9% of proprietary product revenue, a 28.7% increase from RMB 41.1 million in 2022[22]. - The company has established a "Global 4+2" R&D layout with 240 R&D personnel, representing approximately 28% of total employees, and significant investments in various ophthalmic products[22]. Product Development and Market Strategy - The company launched several new products, including a domestically produced rigid gas permeable contact lens and an automated fundus camera, which have shown strong market demand[14]. - The company aims to leverage its extensive experience and product range to capture growth opportunities in the ophthalmic sector[3]. - The company plans to expand its market presence and enhance its product offerings through new technology development and strategic initiatives[3]. - The company is focusing on expanding its presence in Asia and Europe while maintaining its leadership position in the Chinese market[29]. Sales and Revenue Breakdown - Sales of ophthalmic medical equipment reached RMB 680.3 million, while sales of consumables amounted to RMB 510.5 million, both showing growth compared to the previous year[15]. - Revenue from the company's distribution products amounted to RMB 808.9 million, reflecting an 8.6% increase from RMB 744.8 million in 2022, driven by product updates and enhanced marketing efforts[19]. - The revenue contribution from the company's proprietary products reached RMB 381.9 million, accounting for 32.1% of total sales, an increase from 29.3% in 2022, with a year-on-year growth of 23.9%[18]. - The technical services segment generated revenue of RMB 209.2 million, representing a 10.0% year-on-year increase, with over 26,000 service instances provided during the reporting period[21]. Operational and Financial Management - The company has a strong focus on compliance and internal audit, led by Mr. Zhao as the Chief Compliance Officer[68]. - The company’s financial management is overseen by Ms. Li, who has over 21 years of experience in accounting and finance[70]. - The company has maintained a robust cash flow and financial resources to support its operational and expansion needs[56]. - The company recorded income tax expenses of RMB 74.8 million for the year ended December 31, 2023, compared to RMB 77.6 million in 2022[42]. Corporate Governance and Leadership - The company has adopted a corporate governance code to maintain high standards of corporate governance and protect shareholder interests[132]. - The board consists of five executive directors, one non-executive director, and three independent non-executive directors as of December 31, 2023[138]. - The independent non-executive directors play a crucial role in providing impartial views on the company's strategy and performance[141]. - The company has established three board committees: the Audit Committee, the Remuneration Committee, and the Nomination Committee to oversee specific aspects of its affairs[137]. Social Responsibility and ESG Commitment - The company is committed to fulfilling social responsibilities and promoting sustainable growth, as detailed in the Environmental, Social, and Governance report[90]. - The company has identified 21 ESG issues categorized into environmental, social, and governance aspects, with high importance placed on product quality and safety, compliance employment, employee training and development, supply chain management, responsible marketing, information security and privacy protection, and anti-corruption[197]. - The company emphasizes the importance of anti-corruption and risk management in its operations, particularly in compliance with regulations and environmental management[196]. Employee and Talent Management - The total employee cost amounted to RMB 352.5 million, an increase from RMB 288.4 million as of December 31, 2022, reflecting a growth of approximately 22.3%[108]. - The number of employees increased to 869 as of December 31, 2023, up from 790 as of December 31, 2022, indicating a growth of over 10%[108]. - The company emphasizes employee training and development, continuously enhancing its training management system to support long-term high-quality growth[108]. Risk Management and Compliance - The company has established a risk management and internal control system to ensure high levels of corporate governance and to identify and mitigate potential risks[175]. - The board reviewed the effectiveness of the risk management and internal control system for the year ending December 31, 2023, ensuring compliance with established procedures and standards[176]. - The internal audit function plays a key role in monitoring the company's internal governance and reports significant issues to the audit committee[176].

Financial Performance - For the year ended December 31, 2023, the company's revenue was RMB 1,406.2 million, an increase of 12.2% compared to RMB 1,253.8 million for the year ended December 31, 2022[2]. - The net profit for the year ended December 31, 2023, was RMB 172.9 million, a significant recovery from a net loss of RMB 352.7 million in the previous year[2]. - The basic earnings per share for the year ended December 31, 2023, was RMB 1.17, compared to a basic loss per share of RMB 3.61 for the year ended December 31, 2022[2]. - The gross profit for the year ended December 31, 2023, was RMB 691.6 million, reflecting a 10.6% increase from RMB 625.3 million in the previous year[4]. - The company's revenue increased by 12.2% from RMB 1,253.8 million in 2022 to RMB 1,406.2 million in 2023, driven by higher sales of ophthalmic medical consumables and equipment[18]. - Sales of distributed products reached RMB 808.9 million in 2023, up from RMB 744.8 million in 2022, while proprietary products sales increased from RMB 308.3 million to RMB 381.9 million[19]. - Gross profit increased by 10.6% from RMB 625.3 million in 2022 to RMB 691.6 million in 2023, with a slight decrease in gross margin from 49.9% to 49.2%[21]. - The total comprehensive income for the year was RMB 208,753 thousand, compared to a loss of RMB 328,210 thousand in 2022[63]. Revenue Breakdown - Revenue from proprietary products reached RMB 381.9 million, accounting for 32.1% of total sales, up from 29.3% in the previous year[7]. - Revenue from distribution products was RMB 808.9 million, an increase of 8.6% from RMB 744.8 million in the previous year[8]. - The technical services segment generated revenue of RMB 209,234 thousand, up from RMB 190,084 thousand in 2022, showing a growth of approximately 10.6%[84]. - Revenue from the Greater China region was RMB 1,122,722 thousand, up from RMB 1,001,358 thousand in 2022, reflecting a growth of about 12.1%[81]. Research and Development - The R&D team has 240 personnel, accounting for approximately 28% of total employees, with R&D expenditure of RMB 52.9 million, representing 13.9% of proprietary product revenue, an increase of 28.7% from RMB 41.1 million in 2022[10]. - The company aims to increase R&D investment and enhance cooperation with upstream partners to achieve over 50% revenue contribution from proprietary products[17]. - The company’s R&D efforts include the development of an automatic fundus camera and optical biometer, with the automatic fundus camera showing increasing market demand[11]. - Research and development expenses amounted to RMB 52,883,000, up from RMB 41,089,000 in the previous year, marking a growth of 28.7%[92]. Expenses and Costs - The cost of sales rose by 13.7% from RMB 628.4 million in 2022 to RMB 714.6 million in 2023, primarily due to increased raw material costs for proprietary products and higher procurement prices for imported products[20]. - Sales and distribution expenses surged by 32.5% from RMB 187.8 million in 2022 to RMB 248.8 million in 2023, attributed to the resumption of offline marketing activities post-pandemic[23]. - Administrative expenses decreased by 11.5% from RMB 146.2 million for the year ended December 31, 2022, to RMB 129.4 million for the year ended December 31, 2023, primarily due to the absence of listing expenses in 2023[24]. - Financing costs increased by 18.5% from RMB 42.7 million for the year ended December 31, 2022, to RMB 50.6 million for the year ended December 31, 2023, mainly due to rising interest rates on bank and other borrowings[25]. Dividends and Shareholder Returns - The company plans to distribute a final dividend of HKD 1.1 per share for the year ended December 31, 2023, subject to shareholder approval[2]. - The company proposed a final dividend of HKD 1.10 per share for the year ending December 31, 2023, compared to no dividend in 2022, amounting to HKD 162,767,000[102]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and has adopted a corporate governance code[54]. - The chairman and CEO roles are held by the same individual, which the board believes does not affect the balance of power and authority[55]. - The company has established an audit committee to oversee financial reporting and risk management processes[58]. Market Expansion and Strategy - The company has expanded its distribution network, partnering with 19 overseas brands, including Haag-Streit, to enhance its product offerings and market reach[12]. - The company is expanding its market presence in the Greater China region, targeting a 25% increase in market share by 2025[125]. - The company plans to strengthen its market presence in Asia and Europe while balancing domestic and international business growth[17]. Assets and Liabilities - Non-current assets increased to RMB 1,452,881 thousand as of December 31, 2023, from RMB 1,391,756 thousand in 2022[64]. - The company's total equity increased to RMB 1,696,986 thousand as of December 31, 2023, compared to RMB 1,486,685 thousand in 2022[66]. - The total amount of borrowings as of December 31, 2023, was RMB 618,562,000, compared to RMB 701,588,000 in 2022, showing a decrease of 11.8%[118]. Future Outlook - The company has provided a revenue guidance of $85 million for the fiscal year 2024, which reflects a projected growth of approximately 13%[125]. - New product launches are expected to contribute an additional $10 million in revenue in 2024, focusing on innovative medical devices[125]. - The board of directors remains optimistic about the long-term growth trajectory, citing strong fundamentals and a robust pipeline of new products[125].